Biochirp’s Post

𝐏𝐥𝐮𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐍𝐞𝐰 𝐈𝐧𝐭𝐞𝐫𝐢𝐦 𝐑𝐞𝐒𝐏𝐄𝐂𝐓-𝐆𝐁𝐌 𝐏𝐡𝐚𝐬𝐞 𝟐 𝐓𝐫𝐢𝐚𝐥 𝐃𝐚𝐭𝐚 𝐚𝐭 𝐭𝐡𝐞 𝐒𝐨𝐜𝐢𝐞𝐭𝐲 𝐟𝐨𝐫 𝐍𝐞𝐮𝐫𝐨𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐰𝐢𝐥𝐥 𝐇𝐨𝐬𝐭 𝐊𝐞𝐲 𝐎𝐩𝐢𝐧𝐢𝐨𝐧 𝐋𝐞𝐚𝐝𝐞𝐫 𝐖𝐞𝐛𝐢𝐧𝐚𝐫 Plus Therapeutics, Inc. (Nasdaq: PSTV) Plus Therapeutics, Inc. shares encouraging results from the ongoing ReSPECT-GBM Phase 2 trial for rhenium (186Re) obisbemeda, its lead radiotherapeutic designed for recurrent glioblastoma (rGBM). Presented at the Society for NeuroOncology (SNO) 28th Annual Meeting, the data hints at a survival benefit over standard care, underlining potential advancements in glioblastoma treatment. Key Highlights: ReSPECT-GBM Phase 2 trial focuses on assessing overall survival (OS) post-administration of rhenium (186Re) obisbemeda. Preliminary data includes 15 treated rGBM patients, revealing a median overall survival of 13 months, with 9 patients still alive. Median progression-free survival stands at 11 months. Robust tumor coverage is reported, with 87.2% treated tumor volume in 15 patients at 120 hours. Longitudinal imaging analysis supports observed efficacy signals. Safety and tolerability align with Phase 1 trial data, marking rhenium (186Re) obisbemeda as generally safe and well-tolerated. Commentary: Marc H. Hedrick, M.D., M.B.A. Marc Hedrick, President and CEO of Plus Therapeutics, expressed optimism, stating, “We believe the data presented at SNO suggests that rhenium (186Re) obisbemeda confers a survival benefit over published standard of care data and our own real-world data assessments of propensity matched controls.” Principal investigator Dr. Andrew J. Brenner noted the compelling therapeutic rationale and observed Phase 2 clinical outcomes consistent with the Phase 1 trial. The 2024 focus for Plus Therapeutics involves expanding clinical sites, completing Phase 2 enrollment, advancing Phase 1 trials, and planning the next steps for the program. #clinicaltrials #oncology #treatment #therapeutics #tumor #healthcare

This article discusses how small molecule #biomarkers, which can reflect dynamic changes in underlying #tumor composition in response to a drug, can be profiled in patients during #cancer #clinicaltrials to help support timely intervention to introduce, remove, increase, or combine therapies. See why this adaptive approach can help optimize trial outcomes: https://lnkd.in/gU5MAeFc #oncologybiomarkers #doseresponse #adaptiveclinicaltrials

Remember the catchphrase from the #Ginsu knives commercial from the ‘80s: “But wait! There’s more!”? The pharmaceutical equivalent of Ginsu knives is the EpicentRx lead therapy, RRx-001 (nibrozetone), which is potentially active in a whole host of indications from cancer to endometriosis, oral mucositis, myocardial infarction, stroke, pulmonary hypertension, and neurodegenerative diseases. But wait! There’s more - so much more to read in this blog post here: https://bit.ly/45yklCS.

Adjuvant treatment with alectinib generated a statistically significant and clinically meaningful improvement in disease-free survival compared with platinum-based chemotherapy in patients with completely resected stage IB to IIIA, ALK-positive non–small cell #LungCancer. https://lnkd.in/eisfX-Q8

Funding from Europe and the Province of North Brabant for Eindhoven based UPyTher and SupraPolix BV to bring novel and improved therapy to patients with peritoneal cancer, with a total budget of EUR 2.8 million. SupraPolix develops tailored injectable hydrogel gel solutions for various medical applications. Building on this hydrogel technology UPyTher is pioneering an innovative treatment for patients with peritoneal cancer that enables a very efficient delivery of medicines into the peritoneal cavity.    Within the project INJECTOGELS SupraPolix and UPyTher work together to scale-up the production processes of these injectable gels and confirm their safe use as drug delivery platform for intraperitoneal therapy. At the end of the project, UPyTher’s first product for intraperitoneal therapy can be manufactured according to regulatory standards and is supported with a robust nonclinical data package that allows clinical evaluation for patients with peritoneal metastases from colorectal origin. Stimulus Programmamanagement | UPyTher | SupraPolix BV

Another milestone not only for solid tumors and #allogeneic #NK #celltherapy, but also for cryopreserved starting material! The #cryopreservation process allows to maintain significant cellular cytotoxicity, and potentially making hundreds of thousands of #NKcell doses from a single donor. Learn how CPC Services can help your #clinicaltrial patient sample processing and cryopreservation and storage of starting material. www.cpcservices.com https://lnkd.in/eSPurzXs #immunotherapy #cancerresearch #clinicalresearch

The #Prostate_Cancer_Treatment_Market is witnessing remarkable growth with breakthroughs in research and innovation. Cutting-edge therapies, early detection methods, and personalized treatments are transforming the landscape, offering new hope to patients and healthcare providers. This evolving market underscores our commitment to advancing healthcare and improving patient outcomes. Let's join hands to raise awareness, encourage research, and drive innovation, ultimately enhancing the quality of life for those affected by prostate cancer. ✔️𝐒𝐢𝐠𝐧 𝐔𝐩 𝐰𝐢𝐭𝐡 𝐘𝐨𝐮𝐫 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐄𝐦𝐚𝐢𝐥 𝐟𝐨𝐫 𝐀 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dDQRKVnK 𝐏𝐨𝐬𝐬𝐢𝐛𝐥𝐞 𝐑𝐞𝐬𝐭𝐫𝐚𝐢𝐧𝐭 𝐢𝐧 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 The high costs associated with the tissue biopsy for prostate cancer, especially in cases of advanced-stage tumors, might restrain the fledged expansion of the Global Prostate Cancer Market during 2022-27. Besides, high consultation fees and poor reimbursement of treatment expenditures might also act as significant growth restraints for the market in the coming years. Some of the key players in the prostate cancer treatment market include: Abbott, AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai US, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK, Merck Group, Novartis, Pfizer, Sanofi, and many more, #health #healthcare #prostatecancer #healthcareinnovation #medicaladvancements #cancerresearch #marketresearchreports #marketanalysis #marketgrowth #insight #growth #getfreesample #marknteladvisors #consulting

Funding from Europe and the Province of North Brabant for Eindhoven based UPyTher and SupraPolix BV to bring novel and improved therapy to patients with peritoneal cancer, with a total budget of EUR 2.8 million. SupraPolix develops tailored injectable hydrogel gel solutions for various medical applications. Building on this hydrogel technology UPyTher is pioneering an innovative treatment for patients with peritoneal cancer that enables a very efficient delivery of medicines into the peritoneal cavity.    Within the project INJECTOGELS SupraPolix and UPyTher work together to scale-up the production processes of these injectable gels and confirm their safe use as drug delivery platform for intraperitoneal therapy. At the end of the project, UPyTher’s first product for intraperitoneal therapy can be manufactured according to regulatory standards and is supported with a robust nonclinical data package that allows clinical evaluation for patients with peritoneal metastases from colorectal origin. Stimulus Programmamanagement | UPyTher | SupraPolix BV

𝐒𝐢𝐫𝐧𝐚𝐨𝐦𝐢𝐜𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐒𝐮𝐜𝐜𝐞𝐬𝐬𝐟𝐮𝐥 𝐏𝐡𝐚𝐬𝐞 𝐈 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐒𝐭𝐮𝐝𝐲 𝐨𝐟 𝐑𝐍𝐀𝐢 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐒𝐓𝐏𝟕𝟎𝟕 𝐟𝐨𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫𝐬 Sirnaomics Ltd. (Stock Code: 2257.HK) Sirnaomics, a leading biopharmaceutical company focused on RNAi therapeutics, announced completion of dosing for Phase I study of STP707 for treating late-stage solid tumors in unresponsive patients. About 74% achieved stable disease; some saw tumor reduction per RECIST criteria. Dr. Patrick Lu Patrick Lu, Founder and CEO, shared, "This groundbreaking Phase I study shows promising potential for metastasized tumors. STP707 delivered stable disease and tumor reduction in patients." The basket study enrolled 50 late-stage cancer patients unresponsive to prior treatments like surgery and radiation, representing resistant tumor types. Preliminary data indicates 74% achieved stable disease and some experienced tumor shrinkage. Conducted in the US with participation from cancer centers like Mayo Clinic and Yale Cancer Center, the study evaluated safety and efficacy of STP707 at varying doses via intravenous administration. After a 28-day cycle, each dose cohort showed no dose-limiting toxicity, allowing for dose escalation. Dr. Michael Molyneaux Michael Molyneaux, Executive Director and CMO, highlighted STP707's safety profile and encouraging efficacy signals. Patients received various prior treatments, emphasizing the study's significance in resistant tumor subsets. Excitingly, strong safety combined with response duration marks a positive direction. More data to come as treatment and observations conclude. #treatment #patient #therapeutic #clinicaltrials #tumor #disease #safety #healthcare #china #solidtumor

Thrilled to share insights from the recent study on HER2+ breast cancer treatment I took part in. Our research compared the impact of using the subcutaneous fixed-dose combination of pertuzumab + trastuzumab (PH FDC SC) versus the traditional intravenous approach (P+T IV). Here the key findings: - PH FDC SC significantly decreased the time spent by patients in the Day Hospital, particularly thanks to the shorter administration phase. - The subcutaneous administration resulted in reduced personnel time and direct costs for hospitals, showcasing potential economic benefits. - A complete switch to PH FDC SC could lead to increased productivity, enabling hospitals to administer additional oncological therapies. - Patients and caregivers may experience decreased yearly social indirect costs. While our study underscores the economic and organizational advantages of PH FDC SC, it also emphasizes the importance of optimized organizational decisions to mitigate potential delays in oncological patient care. For a detailed exploration of our findings, check out the full article here: https://lnkd.in/dRmQsFcq. Thank you BIP for the opportunity to be involved in such an impactful project!